HOME >> BIOLOGY >> NEWS
Most promising clinical uses for stem cells from fat agreed on by international society

PITTSBURGH, Oct. 5 While questions still remain about the nature and function of stem cells found in fat, a group of researchers and clinicians convened today in Pittsburgh at the Second Annual Meeting of the International Fat Applied Technology Society (IFATS) agreed that research should move forward with the ultimate goal of performing human clinical trials to test the cells' therapeutic potential for specific indications.

Today concludes scientific sessions exploring how adipose tissue, or fat, can be an abundant source of stem cells that could be used for tissue engineering and regenerative medicine. An important outcome of the meeting was the development of a consensus defining key scientific questions for future study and determining the field's most promising clinical applications.

More than 300,000 liposuction procedures are performed in the United States each year, producing about 150,000 gallons of fat that is normally discarded. In 2001, researchers first reported that such tissue contained stem cells, and since then, additional studies have suggested they can be coaxed into other cell types, such as nerve, bone, muscle and blood vessels; or it may be that they have properties of these cells. Some research has progressed more rapidly, with animal studies indicating potential for the development of treatments for heart attack or bone injury, for example, while results looking at other uses are still quite preliminary.

There are currently no human trials in the United States evaluating the potential of stem cells derived from fat, but in reaching consensus on the most promising clinical applications, those attending the IFATS meeting believe the first clinical attempts in patients should be for repairing or healing bone defects, promoting growth of blood vessels in tissues not receiving sufficient blood supply, and for treating acute or chronic cardiac and peripheral vascular diseases.

Moreover, the group felt the
'"/>


5-Oct-2004


Page: 1 2

Related biology news :

1. A new plant-bacterial symbiotic mechanism promising
2. A new plant-bacterial symbiotic mechanism promising for crop applications
3. American Association for Cancer Research provides support for promising cancer scientists
4. Sea creatures toxin could lead to promising cancer treatment
5. Epigenetic drugs, promising for breast cancer treatment
6. New study suggests promising drug combinations for sleeping sickness
7. Analysis of breast-cancer gene role offers promising target
8. Researchers report initial success in promising approach to prevent tooth decay
9. DNA highly promising predictor for successful treatment of alcoholics
10. Stem cells: Chemistry paves way toward promising therapies
11. Is liver damage down the TRAIL for a promising cancer therapy?

Post Your Comments:
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... OncoTAb, Inc., a ... spin-out company, announced today the appointment of physician ... Chief Operating Officer (COO). Cooper brings to OncoTAb ... clinical diagnostic and biotechnology platforms in the fields ... extensive career transcends the field of medical and ...
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... -- Avelas Biosciences, an in vivo cancer ... that it has initiated a Phase 1b study of ... primary, non-recurrent breast cancer undergoing surgery. In commencing the ... Steven Chen , M.D., as vice president of ... study will enroll up to 39 women with stage ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
Cached News: